Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ZBT
|
|||
| Former ID |
DNAP001679
|
|||
| Drug Name |
Crizotinib
|
|||
| Synonyms |
Xalkori (TN); novel ALK inhibitors
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Non-small-cell lung cancer [ICD-11: 2C25.Y; ICD-9: 162] | Approved | [1], [2] | |
| Company |
Pfizer New York, NY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22Cl2FN5O
|
|||
| Canonical SMILES |
CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N
|
|||
| InChI |
1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1
|
|||
| InChIKey |
KTEIFNKAUNYNJU-GFCCVEGCSA-N
|
|||
| CAS Number |
CAS 877399-52-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16729581, 23733583, 74374126, 75543391, 93581001, 99309272, 99437209, 99445171, 103728028, 104161043, 119526687, 121278669, 124490471, 124756975, 125163780, 125299329, 126659900, 131407280, 135264650, 135668295, 135727397, 136345871, 136367829, 136920405, 137232008, 137275901, 141226597, 143499147, 152040652, 152134626, 152237527, 152258843, 152344161, 160644611, 160647693, 160815247, 160969694, 162010188, 162010189, 162011538, 162196520, 162927269, 163565316, 163590241, 164041842, 164193931, 165245564, 170497919, 174531154, 175265614
|
|||
| ChEBI ID |
CHEBI:64310
|
|||
| ADReCS Drug ID | BADD_D00535 | |||
| SuperDrug ATC ID |
L01XE16
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903). | |||
| REF 2 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.